Another pre-clinical study showed that blocking both PD-L1 and TIGIT increased the efficacy of Dinutuximab beta (GD2 antibody) in HRNB tumors in vivo causing complete removal of tumor compared to blocking either TIGIT and PD-L1 separately (82). The gene discussed is CD274; the disease is neoplasm.